Alkylating Agents and Antimetabolites
Alkylating agents and antimetabolites are the two oldest and most fundamental classes of cytotoxic anticancer drugs. Alkylating agents act by covalently modifying DNA, while antimetabolites mimic the natural building blocks of nucleic acids to disrupt their synthesis. Together they form the conceptual foundation of classical chemotherapy and illustrate the central pharmacologic strategy of selectively damaging rapidly dividing cells.
Definition
Alkylating agents are cytotoxic compounds that transfer alkyl groups to nucleophilic sites on DNA (and other macromolecules), producing adducts and cross-links that impair replication; antimetabolites are structural analogs of normal metabolites (purines, pyrimidines, or folate) that competitively inhibit or are incorporated into nucleic-acid synthesis.
Scope
This area orients the reader to the principles shared by the classical cytotoxic agents: how alkylating drugs cross-link or alkylate DNA, how antimetabolites interfere with nucleotide and folate metabolism, and how the cell cycle shapes when these drugs are effective. It frames these as pharmacology reference topics and links to the detailed entries on alkylating agents, purine and pyrimidine analogs, folate antagonists, and cell-cycle scheduling.
Sub-topics
Core questions
- How do alkylating agents damage DNA and why is that damage cytotoxic?
- How do antimetabolites differ mechanistically from agents that directly damage DNA?
- Why does the phase of the cell cycle influence the activity of these drugs?
- What general principles distinguish cell-cycle-specific from cell-cycle-nonspecific agents?
Key concepts
- Covalent DNA alkylation and cross-linking
- Antimetabolite (analog) inhibition of nucleotide synthesis
- Cell-cycle specificity
- Cytotoxic selectivity for dividing cells
- Combination chemotherapy
- Acquired and intrinsic drug resistance
Mechanisms
The two classes attack DNA synthesis from different angles. Alkylating agents are chemically reactive and add alkyl groups to DNA bases, generating monoadducts and interstrand or intrastrand cross-links that block replication and transcription and trigger cell death; their action is largely independent of cell-cycle phase. Antimetabolites instead resemble physiologic metabolites closely enough to occupy the active sites of enzymes in nucleotide and folate pathways or to be incorporated into DNA or RNA as faulty substrates, and they exert their greatest effect during the DNA-synthesis (S) phase. The shared therapeutic rationale is that tumour cells with high proliferative rates are disproportionately vulnerable, though normal proliferating tissues such as marrow and gut epithelium are also affected (Chabner & Roberts, 2005; Goodman & Gilman, 2018).
Clinical relevance
These drug classes underlie much of the curative and palliative chemotherapy used across oncology and remain components of many combination regimens. Understanding their mechanisms is foundational for appraising oncology pharmacology and for interpreting why predictable toxicities affect proliferating normal tissues. This entry describes the pharmacologic basis of the agents and is not a guide to selecting, dosing, or administering treatment.
Evidence & guidelines
The mechanistic basis of alkylating agents and antimetabolites is established textbook pharmacology, summarized in standard references such as Goodman & Gilman's The Pharmacological Basis of Therapeutics. Their historical efficacy traces to Farber's 1948 demonstration of remission in childhood leukemia with the folate antagonist aminopterin, an event widely regarded as the birth of modern cancer chemotherapy (Farber & Diamond, 1948; Chabner & Roberts, 2005).
History
Wartime observations that sulfur mustard suppressed bone marrow led to the first use of nitrogen mustard alkylating agents against lymphoma in the 1940s, while Sidney Farber's 1948 use of aminopterin produced the first temporary remissions in childhood acute leukemia. These two threads, DNA-damaging alkylators and metabolic antagonists, defined the early era of cytotoxic chemotherapy and the strategies of combination therapy that followed (Farber & Diamond, 1948; Chabner & Roberts, 2005).
Key figures
- Sidney Farber
- Bruce Chabner
Related topics
Seminal works
- farber-1948
- chabner-roberts-2005
Frequently asked questions
- What is the basic difference between an alkylating agent and an antimetabolite?
- An alkylating agent chemically damages DNA directly by attaching alkyl groups and forming cross-links, whereas an antimetabolite mimics a natural metabolite to block or corrupt the synthesis of nucleic acids.
- Why are these drugs toxic to normal tissues as well as tumours?
- Because they target processes common to all dividing cells, normal tissues with high turnover such as bone marrow and the gut lining are also affected, which accounts for many of the characteristic toxicities of classical chemotherapy.